Sisu Global Hemafuse

Target SDGs

Market Suggested Retail Price

$50.00

Target Users (Target Impact Group)

Small and Medium-sized Enterprises, Public Sector Agencies, NGOs

Distributors / Implementing Organizations

Hospitals, NGO, governments will buy Sisu Global Hemafuse from Sisu and distribute.

Manufacturing/Building Method

Small-batch medical device production.

Intellectural Property Type

Patent

User Provision Model

The Hemafuse will be available for purchase from Sisu and through VIA Global Health by hospital administrators, medical NGO’s, and Ministries of Health.

Distributions to Date Status

Unknown

Design Specifications

The Hemafuse is a manual autotransfusion device that functions much like a large syringe to pull blood through a filter and to transport it straight to a blood bag in a closed system. The process is illustrated in the image below. One filter for the Hemafuse can transfuse up to four or five pints of blood.  

Product Schematics

Technical Support

Sisu provides training and support and can be contacted via their website.

Replacement Components

Filters are available separately.

Lifecycle

Each patient receives a new filter, but the device can be used up to 50 times before needing to be replaced.

Manufacturer Specified Performance Parameters

Sisu claims that the Hemafuse takes 1/3 of the time, 1/9 of the staff, and is significantly safer than the traditional soup ladle procedure.

Vetted Performance Status

Pre-Clinical testing is currently underway, clinical (human) testing is to be started in late 2015.

Safety

Unknown

Complementary Technical Systems

Unknown

Academic Research and References

Compliance with regulations

None indicated. Applicable international standards are unknown.

Evaluation methods

Field trials tracking parameters such as time required, number of staff required, safety and cleanliness.